- Investing Ideas
- /
- U.S. Biotech Breakthroughs
U.S. Biotech Breakthroughs
Results
48
Biotech stocks worldwide which are expected to become profitable in the next 3 years.
48 companies
Arcturus Therapeutics Holdings
Market Cap: US$470.3m
Engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases.
ARCT
US$18.13
7D
1.6%
1Y
-12.0%
Celcuity
Market Cap: US$2.3b
A clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.
CELC
US$55.07
7D
-11.9%
1Y
263.7%
KalVista Pharmaceuticals
Market Cap: US$707.8m
A biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs.
KALV
US$13.62
7D
-14.7%
1Y
26.5%
GeoVax Labs
Market Cap: US$17.8m
A clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States.
GOVX
US$0.69
7D
-1.6%
1Y
-74.7%
Zai Lab
Market Cap: US$3.6b
A biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.
ZLAB
US$31.92
7D
1.9%
1Y
54.4%
Geron
Market Cap: US$810.3m
A commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
GERN
US$1.27
7D
-7.3%
1Y
-70.9%
Dynavax Technologies
Market Cap: US$1.1b
A commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally.
DVAX
US$9.36
7D
-3.5%
1Y
-16.1%
Assembly Biosciences
Market Cap: US$340.0m
A biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide.
ASMB
US$21.19
7D
-9.1%
1Y
15.5%
Mirum Pharmaceuticals
Market Cap: US$3.7b
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
MIRM
US$74.19
7D
-4.5%
1Y
84.1%
Organogenesis Holdings
Market Cap: US$625.4m
A regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States.
ORGO
US$4.96
7D
4.0%
1Y
73.4%
Apellis Pharmaceuticals
Market Cap: US$3.1b
A commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs.
APLS
US$24.39
7D
-9.4%
1Y
-32.8%
Natera
Market Cap: US$23.1b
A diagnostics company, provides molecular testing services worldwide.
NTRA
US$172.16
7D
2.8%
1Y
32.8%